Vnitr Lek 2017, 63(12):945-948 | DOI: 10.36290/vnl.2017.172

Adiponectin in patients with metabolic syndrome and diseases of the liver, bile ducts and pancreas

Adam Vašura^*, Martin Blaho, Petr Dítě, Tomáš Kupka, Pavel Svoboda, Arnošt Martínek

Gastroenterologické oddělení Interní kliniky LF OU a FN Ostrava

Epidemiological data show that the metabolic syndrome can be diagnosed in up to 30 % of the population. Regarding 5 components of the metabolic syndrome, three of them, in case of positivity (visceral obesity, arterial hypertension, hypertriglyceridemia, changes of HDL-cholesterol levels and type 2 diabetes mellitus), are pathogenic factors which are the most frequently related to cardiovascular diseases, but currently they are also the focus of interest for gastroenterologists. The relationship between non-alcoholic hepatic steatosis, including non-alcoholic steatohepatitis, has been described. Less is known so far about the relation to the pancreas disease, particularly with respect to the status referred to as non-alcoholic fatty pancreas disease. The hormone selectively produced by adipose tissue is adiponectin. This protein is studied as a possible biomarker in people with metabolic syndrome, including obesity. Besides that, there is a question studied whether adiponectin can also play a significant role in the pathogenesis of diseases associated with fat building up in parenchymatous organs. Finding a reliable biomarker for patients with metabolic syndrome or diseases of the liver, biliary system and pancreas in relation to metabolic syndrome, presents a big challenge. And adiponectin is one of the promising biomarkers.

Keywords: adiponectin; biliary disease; metabolic syndrome; pancreatic steatosis; steatohepatitis

Received: July 15, 2017; Accepted: September 11, 2017; Published: December 1, 2017  Show citation